I agree that this site is using cookies. You can find further informations here.
X
Ashida, Toshifumi
95  results:
Search for persons X
?
1

Effectiveness and Persistency of Ustekinumab Treatment for ..:

Ando, Katsuyoshi ; Fujiya, Mikihiro ; Ueno, Nobuhiro...
Crohn's & Colitis 360.  6 (2024)  2 - p. , 2024
Link: https://doi.org/10.1093/..
 
?
2

Effectiveness and Factors Associated with Response to Golim..:

Hirayama, Daisuke ; Motoya, Satoshi ; Ashida, Toshifumi...
Inflammatory Intestinal Diseases.  8 (2023)  3 - p. 115-127 , 2023
Link: https://doi.org/10.1159/..
 
?
3

EP1316: LONG-TERM CLINICAL EFFECTIVENESS OF USTEKINUMAB IN ..:

Ito, Takahiro ; Maemoto, Atsuo ; Katsurada, Takehiko...
Gastroenterology.  162 (2022)  7 - p. S-1099 , 2022
Link: https://doi.org/10.1016/..
 
?
4

Absent X‐linked inhibitor of apoptosis protein expression i..:

Abdrabou, Shimaa Said Mohamed Ali ; Toita, Nariaki ; Ichihara, Shin...
Pediatrics International.  64 (2022)  1 - p. , 2022
Link: https://doi.org/10.1111/..
 
?
5

EP1317: REAL-WORLD CLINICAL OUTCOMES AND PREDICTIVE FACTORS..:

Ando, Katsuyoshi ; Fujiya, Mikihiro ; Ueno, Nobuhiro...
Gastroenterology.  162 (2022)  7 - p. S-1099 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Efficacy and safety of a new vedolizumab subcutaneous formu..:

Kobayashi, Taku ; Ito, Hiroaki ; Ashida, Toshifumi...
Intestinal Research.  19 (2021)  4 - p. 448-460 , 2021
Link: https://doi.org/10.5217/..
 
?
7

Long-Term Clinical Effectiveness of Ustekinumab in Patients..:

Ito, Takahiro ; Maemoto, Atsuo ; Katsurada, Takehiko...
Crohn's & Colitis 360.  2 (2020)  4 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
8

Efficacy and safety of abrilumab, an α4β7 integrin inhibito..:

Hibi, Toshifumi ; Motoya, Satoshi ; Ashida, Toshifumi...
Intestinal Research.  17 (2019)  3 - p. 375-386 , 2019
Link: https://doi.org/10.5217/..
 
?
9

Concerns and Side Effects of Azathioprine During Adalimumab..:

Hisamatsu, Tadakazu ; Matsumoto, Takayuki ; Watanabe, Kenji...
Journal of Crohn's and Colitis.  13 (2019)  9 - p. 1097-1104 , 2019
Link: https://doi.org/10.1093/..
 
?
10

Clinical and Pharmacokinetic Factors Associated With Adalim..:

Watanabe, Kenji ; Matsumoto, Takayuki ; Hisamatsu, Tadakazu...
Clinical Gastroenterology and Hepatology.  16 (2018)  4 - p. 542-549.e1 , 2018
Link: https://doi.org/10.1016/..
 
?
11

Reversible Posterior Leukoencephalopathy Syndrome Associate..:

Kikuchi, Shinsuke ; Orii, Fumika ; Maemoto, Atsuo.
Internal Medicine.  55 (2016)  5 - p. 473-477 , 2016
Link: https://doi.org/10.2169/..
 
?
12

Circulating Interleukin 6 and Albumin, and Infliximab Level..:

Suzuki, Yasuo ; Matsui, Toshiyuki ; Ito, Hiroaki...
Inflammatory Bowel Diseases.  21 (2015)  9 - p. 2114-2122 , 2015
Link: https://doi.org/10.1097/..
 
?
13

Infliximab Extends the Duration until the First Surgery in ..:

Sakatani, Aki ; Fujiya, Mikihiro ; Ito, Takahiro...
BioMed Research International.  2013 (2013)  - p. 1-5 , 2013
Link: https://doi.org/10.1155/..
 
?
14

Ex vivo activation of angiogenic property in human peripher..:

Kawamoto, Toru ; Sasajima, Junpei ; Sugiyama, Yoshiaki...
International Journal of Hematology.  98 (2013)  4 - p. 417-429 , 2013
Link: https://doi.org/10.1007/..
 
?
15

C-reactive protein is an indicator of serum infliximab leve..:

Hibi, Toshifumi ; Sakuraba, Atsushi ; Watanabe, Mamoru...
Journal of Gastroenterology.  49 (2013)  2 - p. 254-262 , 2013
Link: https://doi.org/10.1007/..
 
1-15